Delay and restricted access of new molecules in Turkey compared to the United States and European Union

This study compares the performances of new-molecule (NM) launches in Turkey with those in the European Union and United States for the years 2007-2013. The Thomson Reuters Newport Horizon for Innovators Database is used to identify NMs with a launch date after January 1, 2007, worldwide and marketi...

Full description

Saved in:
Bibliographic Details
Published in:Journal of market access & health policy 2013, Vol.1 (1), p.22799
Main Authors: Şahin, Toros, Yeşil, Atakan, Topcu, Türker
Format: Article
Language:English
Subjects:
access to medicine
Audits
Communication
Data bases
Drug stores
Funding
Good Manufacturing Practice
launch
Marketing
new molecules
Pharmaceutical industry
Price cuts
Product development
Regulation
Regulatory approval
Short Communication
Studies
Turkish pharmaceutical market
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study compares the performances of new-molecule (NM) launches in Turkey with those in the European Union and United States for the years 2007-2013. The Thomson Reuters Newport Horizon for Innovators Database is used to identify NMs with a launch date after January 1, 2007, worldwide and marketing authorization approval after January 1, 2007, in the European Union. The launch dates for the European Union, the United States, and Turkey were retrieved from the same database. Data for Turkey were confirmed via IMS and RxMedia. Out of 183 records identified that are launched in the European Union, the United States, or both, 44 of the NMs are launched in Turkey (24%). The results of this study show that 24% of the NMs that are launched in either the European Union or United States were able to be launched in Turkey with a mean delay of 821 days (2.25 years).
ISSN:2001-6689
2001-6689
DOI:10.3402/jmahp.v1i0.22799